Literature DB >> 23551604

Tissue doppler myocardial velocity imaging in infants and children--a window into developmental changes of myocardial mechanics.

Linda Pauliks1.   

Abstract

In adults, tissue Doppler myocardial velocity imaging (TDI) is a recommended component of routine echocardiography and particularly useful to assess diastolic function of the left ventricle. In contrast, color and pulsed-wave TDI velocities are less accepted in pediatrics, perhaps due to their strong age dependence in children. This review discusses the strengths and limitations of TDI velocity imaging in the pediatric age group. Myocardial velocities increase during normal childhood heart development, starting from fetal life, and these changes vary by cardiac segment. TDI velocity maturation opens an interesting window into the normal development of myocardial mechanics in childhood, but makes it difficult to interpret data in an individual child. Moreover, there is a wider range of normal for any given pediatric age than in adults. Still, TDI has been useful to monitor systolic heart function in children with cardiomyopathy or after heart transplantation. TDI studies revealed diastolic dysfunction in obese children and in cancer survivors with preclinical anthracycline cardiomyopathy. There is a growing body of studies using TDI to assess right heart function in children with congenital heart disease or pulmonary hypertension. Another potential strength of TDI velocities is the study of myocardial dyssynchrony where color TDI is well suited for rapid pediatric heart rates, even on fetal echocardiogram. Quantitative stress echocardiography with TDI is an emerging application in children that already offered insight into heart function in children with tetralogy of Fallot. Therefore, TDI velocity imaging should become part of the routine assessment of heart function in children.
© 2013, Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23551604     DOI: 10.1111/echo.12179

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  7 in total

1.  Why we need to understand the mechanics of developing cardiac sarcomeres in humans.

Authors:  R John Solaro
Journal:  J Physiol       Date:  2016-01-15       Impact factor: 5.182

Review 2.  Transthoracic echocardiography in the evaluation of pediatric pulmonary hypertension and ventricular dysfunction.

Authors:  Martin Koestenberger; Mark K Friedberg; Eirik Nestaas; Ina Michel-Behnke; Georg Hansmann
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

3.  Assessing Myocardial Function in Infants with Pulmonary Hypertension: The Role of Tissue Doppler Imaging and Tricuspid Annular Plane Systolic Excursion.

Authors:  Chalese Richardson; Cynthia Amirtharaj; Dorota Gruber; Denise A Hayes
Journal:  Pediatr Cardiol       Date:  2016-12-19       Impact factor: 1.655

4.  Right ventricular performance using myocardial deformation imaging in infants with bronchopulmonary dysplasia.

Authors:  U Haque; C Stiver; B K Rivera; B Richards; N Ma; C L Cua; C V Smith; C H Backes
Journal:  J Perinatol       Date:  2016-10-05       Impact factor: 2.521

5.  Myocardial Tissue Doppler Velocity in Child Growth.

Authors:  Sun-Ha Choi; Lucy Youngmin Eun; Nam Kyun Kim; Jo Won Jung; Jae Young Choi
Journal:  J Cardiovasc Ultrasound       Date:  2016-03-24

6.  Determinants and Regression Equations for the Calculation of z Scores of Left Ventricular Tissue Doppler Longitudinal Indexes in a Healthy Italian Pediatric Population.

Authors:  Veronica Fibbi; Piercarlo Ballo; Silvia Favilli; Gaia Spaziani; Giovanni B Calabri; Iva Pollini; Alfredo Zuppiroli; Enrico Chiappa
Journal:  Cardiol Res Pract       Date:  2015-11-22       Impact factor: 1.866

7.  Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.

Authors:  Yuze Zhang; Xiaoyan Lin; Yong Chu; Xiaoming Chen; Heng Du; Hailin Zhang; Changsheng Xu; Hong Xie; Qinyun Ruan; Jinxiu Lin; Jie Liu; Jinzhang Zeng; Ke Ma; Dajun Chai
Journal:  Cardiovasc Diabetol       Date:  2021-06-11       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.